Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients
- PMID: 35854166
- DOI: 10.1007/s10067-022-06258-0
Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients
Abstract
Objectives: Our aim was to evaluate the renal response rate of patients with lupus nephritis (LN) undergoing standard treatment during a 2-year follow-up and to investigate its predictive factors.
Methods: A prospective cohort study that enrolled 56 clinically diagnosed LN patients with urinary protein positivity was carried out. All patients underwent standard treatment. All patients were followed up at 6-month intervals for 2 years. Data on renal response and clinical characteristics were collected and analyzed.
Results: Among 56 patients, 27 (48.2%) and 13 (23.2%) patients achieved complete renal response (CR) and partial renal response (PR) at 6 months after induction therapy, respectively, and 42 (75.0%) and 4 (7.1%) patients developed CR and PR at 2 years. Among patients who achieved PR at 6 months, 90.0% achieved CR at 24 months, while only 37.5% of the patients who were unresponsive at 6 months achieved CR. In the multivariable Cox proportional-hazards model, female (OR 6.51, 95% CI 1.23-34.52, p = 0.028), disease duration (OR 0.84, 95% CI 0.73-0.98, p = 0.021), achieving PR within 6 months (OR 8.09, 95% CI 2.06-31.73, p = 0.003), and urine protein/creatinine ratio (UPCR) (OR 0.998, 95% CI 0.996-1.000, p = 0.025) were found to be predictive factors of CR.
Conclusion: A total of 48.2% of patients achieved CR at 6 months of induction therapy, and the response rates gradually increased to 60.7%, 64.3%, and 75.0% at 12, 18, and 24 months. Besides, female, disease duration, partial response within 6 months, and UPCR were predictive factors for a complete renal response. Key Points • We evaluate the renal response rates in Chinese patients with lupus nephritis in the real world for 2 years. • A total of 48.2% and 75.0% of patients achieved a complete response after standard treatment for 6 months and 2 years. • Female, disease duration, partial response within 6 months, and UPCR are predictors of complete renal response.
Keywords: Lupus nephritis; Renal response rate; Systemic lupus erythematosus.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Similar articles
-
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.Arthritis Res Ther. 2024 Feb 20;26(1):54. doi: 10.1186/s13075-024-03275-z. Arthritis Res Ther. 2024. PMID: 38378664 Free PMC article.
-
Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.Lupus. 2024 Jan;33(1):88-95. doi: 10.1177/09612033231219354. Epub 2023 Dec 4. Lupus. 2024. PMID: 38048588
-
Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study.Lupus. 2019 Apr;28(4):501-509. doi: 10.1177/0961203319829827. Epub 2019 Feb 12. Lupus. 2019. PMID: 30755146
-
Rituximab use as induction therapy for lupus nephritis: a systematic review.Lupus. 2020 Jul;29(8):892-912. doi: 10.1177/0961203320928412. Epub 2020 Jun 2. Lupus. 2020. PMID: 32486934
-
New Treatment Options in Lupus Nephritis.Arch Immunol Ther Exp (Warsz). 2022 Mar 17;70(1):11. doi: 10.1007/s00005-022-00647-8. Arch Immunol Ther Exp (Warsz). 2022. PMID: 35298708 Review.
Cited by
-
Clinical and Immunological Factors Associated with the Progression of Lupus Nephritis in a Population from the Colombian Caribbean.Biomedicines. 2024 Sep 9;12(9):2047. doi: 10.3390/biomedicines12092047. Biomedicines. 2024. PMID: 39335560 Free PMC article.
-
Lupus Nephritis Risk Factors and Biomarkers: An Update.Int J Mol Sci. 2023 Sep 25;24(19):14526. doi: 10.3390/ijms241914526. Int J Mol Sci. 2023. PMID: 37833974 Free PMC article. Review.
-
Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: A single-center retrospective study.Rheumatol Int. 2024 Jul;44(7):1283-1294. doi: 10.1007/s00296-024-05579-4. Epub 2024 Mar 28. Rheumatol Int. 2024. PMID: 38546745 Free PMC article.
References
-
- Yu F, Haas M, Glassock R, Zhao MH (2017) Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13(8):483–495. https://doi.org/10.1038/nrneph.2017.85 - DOI - PubMed
-
- Davidson A, Aranow C, Mackay M (2019) Lupus nephritis: challenges and progress. Curr Opin Rheumatol 31(6):682–688. https://doi.org/10.1097/BOR.0000000000000642 - DOI - PubMed - PMC
-
- Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C et al (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55(2):252–262. https://doi.org/10.1093/rheumatology/kev311 - DOI
-
- Ayoub I, Nelson J, Rovin BH (2018) Induction therapy for lupus nephritis: the highlights. Curr Rheumatol Rep 20(10):60. https://doi.org/10.1007/s11926-018-0766-9 - DOI - PubMed
-
- Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64(2):159–168. https://doi.org/10.1002/acr.20683 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials